



The case for core focus among mid-market medical device companies

July 2025


When it really matters.SM

Less is often more.


Experienced professionals know the limits of multitasking—no matter your level of expertise, quality and efficiency begin to suffer when you try to do too many things at once. Like erosion, the effects might be gradual, but they will compound and eventually hit a breaking point. The cracks emerge in time.

Such is the case for midmarket medical device companies today. In search of total addressable market (TAM) expansion and profitable growth, many companies diversified their portfolios through organic and inorganic expansion in past years (see Figure 1). Nonetheless, various macroeconomic and market-specific headwinds have created challenges, and many companies, and not just our client, in the segment have underperformed (see Figure 2). Preliminary data shows mid-market MedTechs are underperforming relative to the health and life sciences (HLS) industry overall, as well as the S&P500.

FIGURE 1: DEAL COUNT AND % OF CROSS-SECTOR M&A DEALS FOR US BASED MEDICAL DEVICE COMPANIES



Source: Capital IQ, M&A transaction for US based Medical Device Companies

FIGURE 2: TOTAL SHAREHOLDER RETURNS¹

	1 Yr. TSR	3 Yr. TSR	5 Yr. TSR
S&P 500	10.7%	12.9%	15.8%
PEER AVG.	(23.9%)	(3.3%)	3.9%
CLIENT VS. PEERS	(16.0%)	(12.5%)	(6.3%)

1. TSR = Total Shareholder Returns = Price Appreciation + Dividend Yield; TSR calculated in local currency; Monthly listed values are end of month, reflects stock price as of 5/08/25.
 Values are indexed to 100 starting from May 2020. Source: FactSet, AlixPartners analysis


This underperformance driven by fragmented management attention and resources compels a new strategic imperative: the need to re-center on a core, which may include divestment of non-core assets. But doing this right is no small task, and it calls for a thoughtful approach. The first challenge is to identify which business(es) should be divested (DivestCo). This requires a disciplined portfolio review, including re-evaluating the strategic plan for the remaining business (RemainCo). Based on the updated RemainCo strategic plan, companies can define the deal perimeter. From there, MedTechs should focus on two priorities: maximizing exit value and quickly transforming RemainCo operations.

Unsuccessful diversification

There is a rationale for MedTech players to diversify their businesses in this mid-market space (~\$1~\$5B range). Spurred in part by sluggish growth in core markets due to slow surgical procedure volume recovery, tighter hospital budgets, and disruptive technologies, companies have looked to white space for growth; however, despite their pursuit of both organic and inorganic paths to product and service diversification, these players lag the market in terms of shareholder return and profitability (see Figure 2).

To illustrate this, let's refer to our experience with clients, normalizing the current (Year 0) share price to \$100 at the intersection of investor expectations for revenue growth and margin. Figure 3 shows how a company could double its shareholder value in the next four or five years. We propose two potential paths to doubling shareholder value. The first focuses on value creation through margin expansion by optimizing operating costs. The second uses a combination of growth and margin expansion. In either scenario, it is critical to manage capital carefully to avoid increasing the growth and margin requirements to generate the additional shareholder value. Divesting the non-core business units (BUs) could help the company both increase margin and pursue a growth path—organic or inorganic—and be better positioned to adapt to changing market conditions.

FIGURE 3: IMPLIED SHARE PRICE AT YEAR 4 STARTING AT 100 AT YEAR 0




Source: Sanitized client financials; AlixPartners analysis

Re-centering on the core to achieve profitable growth

Re-centering on the core and building on a company's unique strengths can lead to sustainable advantages such as price leadership, customer loyalty, and talent retention. Figure 4 illustrates this with an example. Here, BUs 5 and 6 have been shrinking and creating a drag on overall margins. Divesting those two units would potentially allow management to double down on the higher performing and/or core segment of the business—in this case, BU 3.

FIGURE 4: EBITDA MARGIN BY DIVISION: 2025 PLAN



Sources: Sanitized client financials; AlixPartners analysis

Mid-market medical device companies have, in general, struggled to achieve consistent profitable growth. There are notable exceptions, of course. These include companies that have established new platforms, such as Intuitive Surgical's robotic soft-tissue surgery platform, or those that have led paradigm shifts, such as Insulet Corporation's innovations in diabetes care. For a company that has stagnated, however, a key step to regaining momentum is to make a purposeful evaluation to discern its core strength—and then, once that core is more clearly understood, focus on it.

Key to a winning divestiture

If a company wants to re-center by divesting its non-core assets, it should begin with the end in mind—that is, with deliberate strategic planning for the eventual RemainCo. The deal perimeter should be informed by the markets, products, capabilities, and operations that will support the RemainCo's future growth and profitability. Once that informed deal perimeter is determined, the company can then shift its focus to maximizing the exit value of the DivestCo, along with streamlining the RemainCo's operating model.

Maximizing DivestCo value

Priming the DivestCo for a high valuation is inherently challenging for two reasons. First, potential buyer profiles can vary; second, value-creation plans are unique for each bidder. That said, companies can pursue select steps to prepare the DivestCo for exit. One such approach is a buyer-agnostic preparation, which might include streamlining the supply chain, sales channels, and operations—including thoughtful transition service agreement (TSA) scoping. Doing so helps maintain the revenue-generating power and growth runway of the DivestCo. Another approach is buyer-specific. With this approach, a company proactively communicates with bidders during diligence about their specific value-creation plan and offers tailored data validation and potential changes to the deal perimeter (e.g., customer/product validation and operational metrics for G&A optimization).

Internal transformation

It's important to acknowledge that a divestiture will inevitably cause some disorientation in the organization, affecting the operating model of the RemainCo. This means that, at a tactical level, a company will need to develop a well-vetted plan to smoothly transition the business, exit TSAs, and manage stranded costs. At a strategic level, it will need to pursue transformations in key value-creating functions to prepare the RemainCo for profitable growth.

If orchestrated well, a winning divestiture will position a company for accelerated growth, acting on a clear strategy to strengthen and leverage its core. The organization as a whole—and crucially, its operating model—will be redesigned precisely to enable strategic initiatives and investments that fuel profitable growth. To cap it off, going through this process will revitalize the “war chest” for investment, allowing renewed flexibility in capital deployment.

Defining a clear path to profitable growth

While most mature businesses go through a periodic strategy plan review, it's critical to re-define strategy during a contemplated divestiture. Decisions related to setting the deal perimeter should be made only after a company has identified its winning markets and products, as well as the corresponding capabilities and infrastructure it needs to support profitable growth for the RemainCo. Of course, it's also crucial to maximize the value of the DivestCo—a win/win for both ends of the deal.

Now is the time to sharpen your company's focus

For business leaders in the mid-market medical device space, strategies to strengthen the core and build a competitive advantage are nothing new; however, what is unique in today's environment is an increased need for leaders to quickly identify divestiture scenarios and re-define the strategic plan. Companies tend to pay considerable attention to the transaction execution phase of divestitures—which is good. That said, the game is really won or lost by the quality of re-defined strategic planning that companies undertake pre-divestiture, coupled with a focus on executing and capturing the value of key strategic initiatives post-divestiture.

5 key actions for a successful divestiture



Define a **clear winning go-forward strategy** for the RemainCo



Thoughtfully **set deal perimeter balancing** RemainCo strategy and DivestCo value



Pursue “no regrets” DivestCo preparation



Hold bidder-specific value discussions **during diligence**



Transform the RemainCo to right-size operations and **support strategic initiatives**

FOR MORE INFORMATION CONTACT:



Read DuPriest
Partner & Managing Director
rdupriest@alixpartners.com



Duane Selby
Partner & Managing Director
dselby@alixpartners.com



Arnie Basu
Partner
abasu@alixpartners.com



David Simon
Director
dsimon@alixpartners.com



Yas Imanishi
Director
yimanishi@alixpartners.com

ABOUT US

For more than 40 years, AlixPartners has helped businesses around the world respond quickly and decisively to their most critical challenges – circumstances as diverse as urgent performance improvement, accelerated transformation, complex restructuring and risk mitigation.

These are the moments when everything is on the line – a sudden shift in the market, an unexpected performance decline, a time-sensitive deal, a fork-in-the-road decision. But it's not what we do that makes a difference, it's how we do it.

Tackling situations when time is of the essence is part of our DNA – so we adopt an action-oriented approach at all times. We work in small, highly qualified teams with specific industry and functional expertise, and we operate at pace, moving quickly from analysis to implementation. We stand shoulder to shoulder with our clients until the job is done, and only measure our success in terms of the results we deliver.

Our approach enables us to help our clients confront and overcome truly future-defining challenges. We partner with you to make the right decisions and take the right actions. And we are right by your side. When it really matters.

The opinions expressed are those of the authors and do not necessarily reflect the views of AlixPartners, LLP, its affiliates, or any of its or their respective professionals or clients. This article The case for core focus among mid-market medical device companies ("Article") was prepared by AlixPartners, LLP ("AlixPartners") for general information and distribution on a strictly confidential and non-reliance basis. No one in possession of this Article may rely on any portion of this Article. This Article may be based, in whole or in part, on projections or forecasts of future events. A forecast, by its nature, is speculative and includes estimates and assumptions which may prove to be wrong. Actual results may, and frequently do, differ from those projected or forecast. The information in this Article reflects conditions and our views as of this date, all of which are subject to change. We undertake no obligation to update or provide any revisions to the Article. This Article is the property of AlixPartners, and neither the Article nor any of its contents may be copied, used, or distributed to any third party without the prior written consent of AlixPartners.